Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors

US11304929B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Harald WEINSTABL · Wien, AT
• Georg Dahmann · Biberach an der Riß, DE
• Matthias Treu · Wien, AT
• Bernd Wellenzohn · Friedrichshafen, DE
• Stephan Karl Zahn · Wien, AT

Key dates

• Filing date: Mar 13, 2018
• Grant date: Apr 19, 2022
• Expiry date: Mar 7, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention encompasses compounds of formula (I), wherein the groups R1 to R, A1 to A4 and n have the meanings given in the claims and specification, their use as inhibitors of PHGDH, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.